AstraZeneca Pharmaceuticals LP
This article is currently outside of Ballotpedia's coverage scope and does not receive scheduled updates. If you would like to help our coverage scope grow, consider donating to Ballotpedia.
| AstraZeneca Pharmaceuticals LP | |
 | |
| Basic facts | |
| Location: | Wilmington, Del. |
| Top official: | Ruud Dobber, President |
| Year founded: | 1912 |
| Website: | Official website |
As of 2016, AstraZeneca Pharmaceuticals LP was the United States division of AstraZeneca, a global biopharmaceutical research and manufacturing company that produced a portfolio of brand-name pharmaceuticals, including Prilosec, Nexium, and Crestor. The U.S. division did business as AstraZeneca US and was based in Wilmington, Delaware.[1][2][3]
Background
As of 2016, AstraZeneca Pharmaceuticals LP was the United States division of AstraZeneca, a global biopharmaceutical company founded in 1912. The organization did business as AstraZeneca US and ranks as one of the largest pharmaceutical companies in the nation.[2][5]
AstraZeneca produced a number of medications including Crestor, Nexium, Symbicort, and Zoladex. The company specialized in developing medications in the following health areas:[2][5]
- Cardiovascular diseases
- Metabolic diseases
- Respiratory diseases
- Inflammation
- Autoimmune diseases
- Oncology
- Infection
- Neuroscience
Work
Lobbying
The following table displays AstraZeneca's federal lobbying expenditures according to the OpenSecrets:[6]
| Federal lobbying expenditures for AstraZeneca Pharmaceuticals LP, 2010-2015 | ||
|---|---|---|
| Year | Total expenditures | |
| 2015 | $3,048,773 | |
| 2014 | $2,890,000 | |
| 2013 | $4,180,000 | |
| 2012 | $3,570,000 | |
| 2011 | $5,640,000 | |
| 2010 | $5,790,000 | |
Political activity
As of 2016, AstraZeneca Pharmaceuticals LP aimed to support its public policy priorities through participation in the U.S. political process. According to the company's website, AstraZeneca "supports policies that promote market competition, expand coverage for the uninsured, ensure that patient safety is maintained and enhanced, foster and reward innovation, and provide protection for intellectual property."[7]
AstraZeneca made political contributions to federal and state candidates through AZ PAC, its voluntary, employee-funded political action committee. In addition, the company makes direct political contributions within legal guidelines to state candidates and committees. AstraZeneca is also a member of 501(c)(6) professional industry and trade organizations that aim to advocate for the interests of the pharmaceutical industry, such as Pharmaceutical Research and Manufacturers of America (PhRMA).[7]
Ballot measure activity
AstraZeneca opposed the 2016 California Drug Price Standards Initiative (Proposition 61), which proposed to regulate drug prices by requiring state agencies to pay the same prices for prescription drugs as the U.S. Department of Veterans Affairs (VA).[4]
Overview of ballot measure support and opposition
The following table details AstraZeneca's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for AstraZeneca Pharmaceuticals LP | |||
|---|---|---|---|
| Ballot measure | Year | Position | Status |
| California Proposition 61, Drug Price Standards (2016) | 2016 | Opposed[4] |  Defeated
|
Leadership
The following individuals hold leadership positions with AstraZeneca Pharmaceuticals LP as of 2016:[1]
- Ruud Dobber, President, AstraZeneca US and executive vice president, North America
- Arturo Araya, Vice president, oncology
- Rich Buckley, Vice president, North America corporate affairs
- Tosh Butt, Vice President, respiratory
- Mike Crichton, Vice president, cardiovascular and metabolic diseases
- Ed Dybka, President, AstraZeneca Canada Inc.
- Greg Keenan, Vice president, medical affairs and US head medical officer
- John McKenna, US chief financial officer and vice president, finance, North America
- Kathy Monday, Regional vice president, supply, Americas
- William Mongan, Vice president, business development, new product planning and mature brands
- Diane Sullivan, Vice president, market access and patient strategies
- Trudy Tan, Vice president, compliance, North America
- Lori Tierney, Vice president, commercial operations
- Tom Valerio, Executive director, regional planning
Recent news
The link below is to the most recent stories in a Google news search for the terms AstraZeneca Pharmaceuticals LP. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
- California Proposition 61, Drug Price Standards (2016)
- California 2016 ballot measures
- Healthcare policy in California
- Pharmaceutical Research and Manufacturers of America (PhRMA)
External links
Footnotes
- ↑ 1.0 1.1 AstraZeneca, "AstraZeneca in the United States," accessed October 6, 2016
- ↑ 2.0 2.1 2.2 Hoovers, "Astrazeneca Pharmaceuticals LP Company Information," accessed October 6, 2016
- ↑ DrugWatch.com, "AstraZeneca," accessed October 26, 2016
- ↑ 4.0 4.1 4.2 California Fair Political Practices Commission, "November 2016 General Election," accessed October 2, 2016, 2016
- ↑ 5.0 5.1 Bloomberg, "Company Overview of AstraZeneca Pharmaceuticals LP," accessed October 6, 2016
- ↑ Center for Responsive Politics, "AstraZeneca PLC," accessed October 26, 2016
- ↑ 7.0 7.1 AstraZeneca, "Political contributions," accessed October 26, 2016
| |||||||
